Novel Inflammatory Prognostic Markers in Lung Cancer Patients Treated with Definitive Chemoradiotherapy
Abstract
Primary lung cancer is the most common cancer worldwide and is an increasingly common problem. The primary endpoint of this study was; to investigate the effect of radiotherapy dose and neutrophil-lymphocyte ratio (NLR) on overall survival (OS) and progression-free survival (PFS). We retrospectively examined 99 patients who were stage III A and stage III B at the time of diagnosis, who did not receive surgical treatment, and who received definitive chemoradiotherapy. Data of patients such as sex, age, ECOG status, tumor location, pathological subtype, radiotherapy dose, type of chemotherapy, neutrophil/lymphocyte ratio (NLR), and some biochemical parameters and PFS and OS were included in the study by scanning the patient's files. The radiotherapy cut-off value was accepted as 60 Gray. OS was statistically better in patients who received radiotherapy at doses of 60 Gray and above. When the patients with radiotherapy dose less than 60 Gy and patients with more than 60 Gray were evaluated in two groups, the overall survival was 8,569 ± 1,404 / month and 14,326 ± 1,209 / month, respectively. (p <0.05). When we evaluate the patients based on NLR; It was observed that the overall survival of patients below NLR 4 at the time of diagnosis was statistically significantly better. The overall survival of patients with NLR <4.0 and NLR> 4 was 14.32 ± 1.30 / month and 10.54 ± 1.16 / month, respectively. (p <0.05)
Keywords
Lung Cancer, Definitive Chemoradiotherapy, Prognostic Markers.
Supporting Institution
Herhangi bir kurum yada kuruluştan destek alınmadı.
Project Number
2018/21-11
Thanks
Makalemi degerlendırmeye aldıgınız için çok teşekkür ederim.
References
- 1. McGuire S. World Cancer Report 2014. Geneva, Switzerland: World Health Organization, International Agency for Research on Cancer, WHO Press, 2015. Adv Nutr An Int Rev J. 2016;7:418–9.
- 2. Bunn PA. Worldwide overview of the current status of lung cancer diagnosis and treatment. In: Archives of Pathology and Laboratory Medicine. 2012. p. 1478–81.
- 3. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.
- 4. Ridge CA, McErlean AM, Ginsberg MS. Epidemiology of lung cancer. Semin Intervent Radiol. 2013;30:93–8.
- 5. Spiro SG, Porter JC. Lung cancer--where are we today? Current advances in staging and nonsurgical treatment. Am J Respir Crit Care Med. 2002;166:1166–96. 6. Alberg AJ. Cancer: Epidemiology of Lung Cancer. Encycl Hum Nutr. 2012;1–4:259–64.
- 7. Dela Cruz CS, Tanoue LT, Matthay RA. Lung cancer: epidemiology, etiology, and prevention. Clin Chest Med. 2011;32:605–44.
- 8. Inamura K. Lung Cancer: Understanding Its Molecular Pathology and the 2015 WHO Classification. Front Oncol. 2017;7:193.
- 9. Travis WD. Pathology of Lung Cancer. Clin Chest Med. 2011;32:669–92.
- 10. Masel EK, Berghoff AS, Füreder LM, Heicappell P, Schlieter F, Widhalm G, Gatterbauer B, Dieckmann U, Birner P, Bartsch R, Schur S, Watzke HH, Zielinski CC, Preusser M. Decreased body mass index is associated with impaired survival in lung cancer patients with brain metastases: A retrospective analysis of 624 patients. Eur J Cancer Care (Engl). 2017;26:e12707.
- 11. Zhu Q-Q, Wang C, Chen Y-Y, Ding Z-Y. Impaired Liver Function Implied Shorter Progression Free Survival for EGFR Tyrosine Kinase Inhibitors. Asian Pac J Cancer Prev. 2018;19:2177–81.